GlycoNex Inc. is a Taiwan-based company principally engaged in the development and licensing of anti-cancer monoclonal antibodies, as well as the provision of carbohydrate antigen and protein drug related commission services. The Company is mainly involved in the development of anti-cancer monoclonal antibody new drugs and bio-similar drugs, as well as the licensing of monoclonal antibody targets and carbohydrate antigen and protein drug related services. The Company distributes its products in domestic market and to overseas markets, such as the rest areas of Asia.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
07/26/07	NT$23.00	+1.10%	1,28,983
06/26/06	NT$22.75	-0.22%	81,257
05/26/05	NT$22.80	+1.79%	1,68,265
02/26/02	NT$22.40	+1.13%	1,98,012
01/26/01	NT$22.15	-0.89%	83,384

End-of-day quote Taipei Exchange

More quotes

End-of-day quote Taipei Exchange 06/10/2026			5-day change	1st Jan Change
22.75 ^TWD	-0.22%		+4.84%	-11.65%

13/08	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
03/08	GlycoNex Inc Doses First Patient In Phase I Trial Of GNX1021	CI

Market Cap	258.8Cr 8.12Cr 7.26Cr 6.77Cr 6.15Cr 12Cr 785.56Cr 12Cr 81Cr 32Cr 399.51Cr 30Cr 30Cr 1.28TCr	P/E 2024	-11.8x	P/E 2025	-11.9x
Enterprise Value	236.83Cr 7.43Cr 6.64Cr 6.19Cr 5.63Cr 11Cr 718.87Cr 11Cr 74Cr 29Cr 365.6Cr 28Cr 27Cr 1.18TCr	EV / Sales 2024	154x	EV / Sales 2025	67.8x
Free-Float	79.89%	Yield 2024 *	-	Yield 2025	-

13/08	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
03/08	GlycoNex Inc Doses First Patient In Phase I Trial Of GNX1021	CI
11/06	Glyconex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar Spd8	CI
14/05	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
15/04	GlycoNex, Inc Receives PMDA Approval To Initiate First-In-Human Phase 1 Trial Of GNX1021 In Gastrointestinal Cancers	CI
23/03	GlycoNex Inc. And Nippon Kayaku Co., Ltd. Enters Collaboration To Advance Next-Generation ADC Candidate	CI
14/03	GlycoNex Incorporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
08/12	GlycoNex Signs CDMO Service Agreement with Change Cure to Advance HMGB1-Targeted Antibody Program	CI
24/11	Glyconex, Inc. and Hokkaido University Hospital Launch Study to Advance Glycan-Directed ADC Development in Gastric Cancer	CI
14/11	GlycoNex Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
29/25/29	GlycoNex announces last patient dosed in phase 3 trial of SPD8, a denosumab biosimilar for osteoporosis	RE
29/25/29	GlycoNex, Inc. Announces Last Patient Dosed in Phase 3 Trial of SPD8, a Denosumab Biosimilar for Osteoporosis	CI
13/25/13	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI

1 day	-0.22%
1 week	+4.84%
Current month	+1.79%
1 month	+2.94%
3 months	-13.66%
6 months	-2.78%
Current year	-11.65%

GlycoNex Incorporation Share Price

Stocks

4168

TW0004168000

Biotechnology & Medical Research

Valuation: GlycoNex Incorporation

Chart: GlycoNex Incorporation

Latest news: GlycoNex Incorporation

Press Releases: GlycoNex Incorporation

Quotes and Performance

Price Extremes

Managers and Directors: GlycoNex Incorporation

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 week	22.1	23.55
1 month	21.05	23.55
Current year	21.05	30
1 year	20.55	30
3 years	15.6	31.85
5 years	15.6	46.9
10 years	10.2	46.9

Manager	Title	Age	Since
Mei Chun Yang CEO	Chief Executive Officer	-	01/01/2019
Dih Fen Wu DFI	Director of Finance/CFO	-	01/01/2010
Yao Hua Lue IRC	Investor Relations Contact	-	12/11/2012

Director	Title	Age	Since
Tong Hsuan Chang CHM	Chairman	-	01/02/2001
Kao Chung Tsai BRD	Director/Board Member	64	-
Ling-Chun Tsai BRD	Director/Board Member	-	25/05/2012

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GLYCONEX INCORPORATION	-0.22%	+4.84%	-8.63%	-20.04%	8.12Cr
WUXI APPTEC CO., LTD.	+4.16%	+4.16%	+49.37%	+94.17%	7.47TCr
ARGENX SE	-15.12%	-15.42%	+3.58%	+52.42%	5.87TCr
LONZA GROUP AG	-1.70%	+1.14%	+4.07%	+32.17%	4.84TCr
REVOLUTION MEDICINES, INC.	+0.50%	-2.14%	+331.33%	+702.20%	4.31TCr
IQVIA HOLDINGS INC.	-0.72%	-3.99%	+28.50%	+29.94%	4.25TCr
BEONE MEDICINES AG	+0.34%	-0.52%	+6.56%	+109.35%	4.14TCr
CELLTRION, INC.	-0.11%	+1.96%	+9.19%	+52.66%	3.13TCr
BIONTECH SE	-0.50%	-3.10%	-10.19%	-14.35%	2.39TCr
INSMED INCORPORATED	-3.32%	-10.86%	-37.32%	+316.28%	2.22TCr
Average	-1.67%	-1.78%	+37.65%	+135.48%	3.86TCr
Weighted average by Cap.	-1.92%	-1.56%	+49.34%	+145.08%

	2024	2025
Net sales	1.47Cr 5L 4L 4L 3L 7L 4.46Cr 7L 46.21L 18.05L 2.27Cr 17.32L 16.94L 7.3Cr	3.79Cr 11.88L 10.61L 10L 9L 16.94L 11Cr 17.07L 1.19Cr 46.49L 5.84Cr 44.6L 43.64L 19Cr
Net income	-23Cr -72.08L -64.4L -60.08L -54.58L -1.03Cr -70Cr -1.04Cr -7.22Cr -2.82Cr -35Cr -2.71Cr -2.65Cr -113.99Cr	-24Cr -73.81L -65.95L -61.53L -55.89L -1.05Cr -71Cr -1.06Cr -7.39Cr -2.89Cr -36Cr -2.77Cr -2.71Cr -116.73Cr
Net Debt	-44Cr -1.39Cr -1.24Cr -1.16Cr -1.05Cr -1.98Cr -134.2Cr -1.99Cr -14Cr -5.43Cr -68Cr -5.21Cr -5.1Cr -219.4Cr	-22Cr -68.94L -61.6L -57.47L -52.2L -98.31L -67Cr -99.04L -6.91Cr -2.7Cr -34Cr -2.59Cr -2.53Cr -109.03Cr